Abstract: The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.
Type:
Grant
Filed:
February 27, 2015
Date of Patent:
September 8, 2020
Assignee:
NANTBIOSCIENCE, INC.
Inventors:
Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
Abstract: The invention relates to a method of modeling K-Ras proteins with one or more mutations that result in constitutive activity, and identifying compounds that inhibit interactions among activated K-Ras proteins and their upstream and downstream effectors.
Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
Abstract: The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
Type:
Grant
Filed:
November 4, 2013
Date of Patent:
November 22, 2016
Assignee:
NantBioScience, Inc.
Inventors:
Chunlin Tao, Chengzhi Yu, Forrest Arp, Paul Weingarten, Patrick Soon-Shiong
Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
Type:
Grant
Filed:
November 5, 2013
Date of Patent:
October 4, 2016
Assignee:
NantBioScience, Inc.
Inventors:
Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
Abstract: The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
August 9, 2016
Assignee:
NantBioScience, Inc.
Inventors:
Chunlin Tao, Qinwei Wang, David Ho, Laxman Nallan, Tulay Polat, Xiaowen Sun, Neil Desai
Abstract: The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.
Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
Type:
Application
Filed:
November 5, 2013
Publication date:
October 15, 2015
Applicant:
NantBioScience, Inc.
Inventors:
Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
Abstract: The invention provides Triazine derivatives and further provides methods of using these compounds to modulate protein kinases and for treating diseases and conditions mediated by protein kinases.
Type:
Grant
Filed:
June 9, 2010
Date of Patent:
July 14, 2015
Assignee:
NantBioScience, Inc.
Inventors:
Chunlin Tao, Qinwei Wang, Laxman Nallan, Tulay Polat, David Ho, Neil Desai
Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
February 3, 2015
Assignee:
NantBioScience, Inc.
Inventors:
Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong